We are adding a dividend stock to our recommended list today.
Name Being Added
Abbvie (ABBV) is the pharma play recently spun off from Abbott Labs (ABT). The company has debuted with a 4.30% plus dividend yield and recently offered up conservative guidance for 2013, which make the stock’s current valuation a decent risk/reward for income investors. The company has a solid pipeline of drugs it has in development, so profits should continue to be steady in the years ahead.